ZBIO Q4 2024 Earnings — Zenas BioPharma, Inc. Revenue & Financial Results | Market Cap Arena

ZBIOZenas BioPharma, Inc.

$1B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M

Gross Profit

$5M100.0% margin

Operating Income

-$56M-1112.5% margin

Net Income

-$53M-1052.1% margin

EPS (Diluted)

$-1.26

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$39M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$370M

Total Liabilities

$58M

Stockholders' Equity

$312M

Cash & Equivalents

$320M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$0	—
Gross Profit	$5M	-$20M	+124.5%
Operating Income	-$56M	-$25M	-124.5%
Net Income	-$53M	-$25M	-114.0%